Takeda Moves Takhzyro Toward Dominant Position In Pediatric HAE
Executive Summary
The company announced data from the Phase III SPRING study of Takhzyro in children aged 2-11; there is no approved long-term prophylactic therapy for children under 6.
You may also be interested in...
Takeda Sees Mainstays Tiding It Over Upcoming Expiries
As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."
Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains
While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.
Scrip’s Top Five Stories Of 2018
A look back at the Scrip stories that piqued the most interest for our readers in 2018.